Loading
A phase 1/2 trial of bevacizumab (glioblastoma use), fOLFIRI (5-FU, leucovorin, irinotecan), fOLFOX (5-FU, leucovorin, oxaliplatin) and temozolomide in colorectal cancer, run by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, now recruiting.
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. is a phase 1/2, interventional study registered as NCT04689347 by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, with a registry enrolment figure of 27 participants, started 2021-01-01 and due to reach its primary completion in 2026-04-30. Interventions recorded: Bevacizumab; Irinotecan; Leucovorin; 5Fluorouracil; Temozolomide. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: (Phase 1b) safety and to determine the recommended phase 2 dose of the combination of FLIRT- bevacizumab in patients with MGMT silenced and MSS mCRC, previously untreated for advanced disease. (Phase 2) efficacy of FLIRT/bev. Colorectal eligibility wording from the registry: "Histologically confirmed metastatic adenocarcinoma of the colon and/or rectum". Sites: Italy. No results are recorded here; the registry entry is the source.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Topoisomerase-I inhibitors (and ADC payloads) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.